Latest Content

The decision removes the triple-class–refractory requirement and allows melflufen use after at least 2 prior lines of therapy.

Anktiva plus BCG improved efficacy vs BCG alone in cohort A of QUILT-2.005 in BCG-naive NMIBC.

The FDA set a June 25, 2027, target action date for gedatolisib plus fulvestrant in PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer.

Read a refresh of hematologic cancer FDA news from October 2026, including the approval of a noncovalent BTK inhibitor in untreated CLL/SLL.

SER-155 showed early promise in reducing bloodstream infections in patients undergoing donor stem cell transplants for blood cancers.

Advances in endocrine therapy, immunotherapy, and ADCs frame unresolved breast cancer treatment questions ahead of BTG 2026.

During a recent OncLive Peer Exchange, multiple myeloma experts discussed how BCMA-directed therapies can be selected and sequenced.

Trine Jakobi Nøttrup, MD, PhD, discusses data for the hTERT-directed vaccine UV1 in BRCA wild-type recurrent ovarian cancer/

Pooled phase 1/2 data support 10 mg/kg every 3 weeks as the provisional pivotal dose of the PD-1/VEGF bispecific antibody cesalatamig in previously treated NSCLC.

Invikafusp alfa plus sacituzumab govitecan produced responses and disease control in metastatic TNBC and HR-positive/HER2-negative breast cancer.

The top 5 OncLive TV videos of the week cover insights in NSCLC, gynecologic cancers, CRC, multiple myeloma, and NMIBC.

A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.

The IL-12–expressing self-replicating mRNA STX-001 showed a favorable therapeutic window at 100 µg, with regression in both injected and non-injected lesions.

Most of the survival time accrued with RP1 plus nivolumab in the IGNYTE trial was spent in good health among patients with advanced melanoma after anti–PD-1 therapy.

VET3-TGI produced responses in injected and non-injected lesions without dose-limiting toxicities in the phase 1/1b STEALTH-001 trial.

IL-1β blockade with canakinumab was well tolerated and reduced nodule size in patients with high-risk indeterminate pulmonary nodules.

VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.

EVX-01 plus pembrolizumab generated sustained neoantigen-specific T-cell responses in advanced melanoma.

IDP-023 plus isatuximab was tolerable and generated responses in heavily pretreated relapsed/refractory multiple myeloma.

David VanderWeele, MD, PhD, reviews where lutetium Lu 177 vipivotide tetraxetan fits across metastatic prostate cancer, how to select and manage patients, and the new radionuclides, targeting molecules, and antigens under investigation.

Longer follow-up of CAPItello-281 showed capivasertib plus abiraterone extended survival in PTEN-deficient hormone-sensitive prostate cancer.

Joshua J. Meeks, MD, PhD, explains how enfortumab vedotin plus pembrolizumab is reshaping organ preservation in MIBC.

Katie S. Murray, DO, discusses how efficacy, toxicity, patient preferences, and treatment logistics guide BCG-unresponsive NMIBC care.

Vignesh T. Packiam, MD, reviews why improved BCG outcomes support its first-line use, with gemcitabine/docetaxel as a BCG-sparing option.

Experts break down key gastrointestinal cancer data and trends from the 2026 ESMO Congress.

Experts break down key melanoma data and trends from the 2026 ESMO Congress.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.

Durvalumab plus BCG is now an approved first-line option for high-risk NMIBC, but better BCG delivery and biomarker-guided selection should shape its use.

The FDA has approved amivantamab and hyaluronidase-lpuj for metastatic head and neck squamous cell carcinoma.

A UCLA-led study suggests routine mammograms or other breast imaging may not benefit women after double mastectomy for DCIS.

Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.

Are we ready to “take that fork in the road” and move palliative/supportive care into routine cancer care?

Lutetium Lu 177 vipivotide tetraxetan showed a median overall survival of 13.1 months in the French PSMA-REACH mCRPC cohort.

Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.

Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.

Yale experts address borderline resectability, perioperative chemoimmunotherapy, pCR-guided adjuvant therapy, and osimertinib in early-stage NSCLC.

Lirafugratinib was added as a category 2A subsequent-line option for cholangiocarcinoma with an FGFR2 fusion or rearrangement and disease progression.

Annual meeting focused on immune set points andthe regulatory mechanisms shaping the next generation of cancer immunotherapies.

The FDA granted priority review to an sNDA for zanubrutinib plus rituximab in untreated mantle cell lymphoma.

Alembic's generic venetoclax, therapeutically equivalent to Venclexta, received final FDA approval for CLL/SLL and newly diagnosed AML.

Misty D. Shields, MD, PhD, answers questions on ADCs, tarlatamab sequencing, first-line maintenance, subtyping, and transformed SCLC.

See what leading breast oncologists have to say about practice-informing data to come out of the 2026 ESMO Congress.